CVX · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $184.43B | $193.41B | $196.91B | $235.72B | $155.61B | $94.47B | $139.87B | $158.90B |
| Cost of Revenue | $108.21B | $119.21B | $119.20B | $145.42B | $92.25B | $52.15B | $80.11B | $94.58B |
| Research & Development | $427.00M | $353.00M | $320.00M | $268.00M | $268.00M | $435.00M | $500.00M | $453.00M |
| Selling, General & Administrative | $5.13B | $4.83B | $4.14B | $4.31B | $4.01B | $4.21B | $4.14B | $3.84B |
| Operating Expenses | $169.29B | $175.29B | $171.37B | $196.58B | $140.83B | $102.14B | $140.98B | $145.76B |
| Interest Expense | $1.22B | $594.00M | $469.00M | $516.00M | $712.00M | $697.00M | $798.00M | $748.00M |
| Income Before Taxes | $19.74B | $27.51B | $29.58B | $49.67B | $21.64B | -$7.45B | $5.54B | $20.57B |
| Provision for Income Taxes | $7.26B | $9.76B | $8.17B | $14.07B | $5.95B | -$1.89B | $2.69B | $5.71B |
| Net Income | $12.30B | $17.70B | $21.40B | $35.50B | $15.60B | -$5.54B | $2.92B | $14.82B |
| Basic EPS | $6.65 | $9.76 | $11.41 | $18.36 | $8.15 | -$2.96 | $1.55 | $7.81 |
| Diluted EPS | $6.63 | $9.72 | $11.36 | $18.28 | $8.14 | -$2.96 | $1.54 | $7.74 |
| Basic Shares Outstanding | 1.85B | 1.81B | 1.87B | 1.93B | 1.92B | 1.87B | 1.88B | 1.90B |
| Diluted Shares Outstanding | 1.86B | 1.82B | 1.88B | 1.94B | 1.92B | 1.87B | 1.90B | 1.91B |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Dec 2026 | $15.72 | $13.67 | $18.10 | 8 | ↑4 ↓2 |
| Dec 2027 | $13.57 | $10.37 | $16.68 | 8 | ↑2 ↓4 |
| Dec 2028 | $12.78 | $11.25 | $16.45 | 4 | ↑0 ↓2 |
| Dec 2029 | $12.92 | $12.08 | $13.76 | 2 | ↑0 ↓0 |